BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 28712693)

  • 1. Diagnostic performance of contrast-enhanced CT-scan in sinusoidal obstruction syndrome induced by chemotherapy of colorectal liver metastases: Radio-pathological correlation.
    Cayet S; Pasco J; Dujardin F; Besson M; Orain I; De Muret A; Miquelestorena-Standley E; Thiery J; Genet T; Le Bayon AG
    Eur J Radiol; 2017 Sep; 94():180-190. PubMed ID: 28712693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis.
    Stevenson HL; Prats MM; Sasatomi E
    BMC Cancer; 2017 Jan; 17(1):35. PubMed ID: 28061766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnetic resonance assessment of sinusoidal obstruction syndrome after neoadjuvant chemotherapy for colorectal liver metastases is not reproducible.
    Staal FC; Beets-Tan RG; Heeres BC; Houwers J; de Boer M; van Dorth D; Lambregts DM; Maas M
    Acta Radiol; 2021 Sep; 62(9):1133-1141. PubMed ID: 32972213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome.
    Soubrane O; Brouquet A; Zalinski S; Terris B; Brézault C; Mallet V; Goldwasser F; Scatton O
    Ann Surg; 2010 Mar; 251(3):454-60. PubMed ID: 20160638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic Parenchymal Heterogeneity as a Marker for Oxaliplatin-Induced Sinusoidal Obstruction Syndrome: Correlation With Treatment Response of Colorectal Cancer Liver Metastases.
    Han NY; Park BJ; Yang KS; Kim MJ; Sung DJ; Sim KC; Cho SB
    AJR Am J Roentgenol; 2017 Nov; 209(5):1039-1045. PubMed ID: 28813196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic Parenchymal Heterogeneity on Contrast-enhanced CT Scans Following Oxaliplatin-based Chemotherapy: Natural History and Association with Clinical Evidence of Sinusoidal Obstruction Syndrome.
    Han NY; Park BJ; Kim MJ; Sung DJ; Cho SB
    Radiology; 2015 Sep; 276(3):766-74. PubMed ID: 25822471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
    Imai K; Emi Y; Iyama KI; Beppu T; Ogata Y; Kakeji Y; Samura H; Oki E; Akagi Y; Maehara Y; Baba H;
    Eur J Surg Oncol; 2014 May; 40(5):559-566. PubMed ID: 24388740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab.
    Hubert C; Sempoux C; Humblet Y; van den Eynde M; Zech F; Leclercq I; Gigot JF
    HPB (Oxford); 2013 Nov; 15(11):858-64. PubMed ID: 23458554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization.
    Narita M; Oussoultzoglou E; Chenard MP; Fuchshuber P; Rather M; Rosso E; Addeo P; Jaeck D; Bachellier P
    Ann Surg Oncol; 2012 Jul; 19(7):2230-7. PubMed ID: 22402811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases.
    Shin NY; Kim MJ; Lim JS; Park MS; Chung YE; Choi JY; Kim KW; Park YN
    Eur Radiol; 2012 Apr; 22(4):864-71. PubMed ID: 22108766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab improves splenomegaly and decreases production of hyaluronic acid after L-OHP based chemotherapy.
    Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T; Hanaoka J; Kanamoto M; Iwahashi S; Saito Y; Yamada S; Asanoma M; Takasu C; Bando Y
    Anticancer Res; 2014 Apr; 34(4):1953-8. PubMed ID: 24692731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases.
    Morris-Stiff G; White AD; Gomez D; Cameron IC; Farid S; Toogood GJ; Lodge JP; Prasad KR
    Eur J Surg Oncol; 2014 Aug; 40(8):1016-20. PubMed ID: 24370284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model.
    Robinson SM; Mann J; Vasilaki A; Mathers J; Burt AD; Oakley F; White SA; Mann DA
    J Hepatol; 2013 Aug; 59(2):318-26. PubMed ID: 23624001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases.
    Vreuls CP; Van Den Broek MA; Winstanley A; Koek GH; Wisse E; Dejong CH; Olde Damink SW; Bosman FT; Driessen A
    Histopathology; 2012 Aug; 61(2):314-8. PubMed ID: 22571348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): Multicentric study of patients operated for colorectal liver metastases.
    Hubert C; Lucidi V; Weerts J; Dili A; Demetter P; Massart B; Komuta M; Navez J; Reding R; Gigot JF; Sempoux C
    Eur J Surg Oncol; 2018 Oct; 44(10):1532-1538. PubMed ID: 30093084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival.
    Viganò L; Capussotti L; De Rosa G; De Saussure WO; Mentha G; Rubbia-Brandt L
    Ann Surg; 2013 Nov; 258(5):731-40; discussion 741-2. PubMed ID: 24045448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases.
    van den Broek MA; Vreuls CP; Winstanley A; Jansen RL; van Bijnen AA; Dello SA; Bemelmans MH; Dejong CH; Driessen A; Olde Damink SW
    Ann Surg Oncol; 2013 May; 20(5):1462-9. PubMed ID: 23463086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gd-EOB-DTPA-enhanced MR findings in chemotherapy-induced sinusoidal obstruction syndrome in colorectal liver metastases.
    Ding Y; Rao SX; Wang WT; Chen CZ; Li RC; Zeng M
    J Int Med Res; 2020 Jun; 48(6):300060520926031. PubMed ID: 32500783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Splenic volume as a biomarker of hepatic damage after chemotherapy in patients with resected colorectal liver metastases (CRLM).
    Saez-Carlin P; García-Botella A; Diez-Valladares LI; Ortega Medina L; Méndez R; González JCM; Bernal I; Serrano García I; Avellana R; Torres García AJ
    Clin Transl Oncol; 2020 Jul; 22(7):1180-1186. PubMed ID: 31758496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases.
    Morris-Stiff G; Tan YM; Vauthey JN
    Eur J Surg Oncol; 2008 Jun; 34(6):609-14. PubMed ID: 17764887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.